21,653 Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) Bought by Quantbot Technologies LP

Quantbot Technologies LP purchased a new stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 21,653 shares of the technology company’s stock, valued at approximately $169,000.

Several other institutional investors have also added to or reduced their stakes in COGT. Victory Capital Management Inc. purchased a new position in Cogent Biosciences in the 3rd quarter worth about $113,000. Intech Investment Management LLC bought a new position in Cogent Biosciences during the 3rd quarter worth about $307,000. Charles Schwab Investment Management Inc. lifted its position in shares of Cogent Biosciences by 20.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 825,793 shares of the technology company’s stock worth $8,919,000 after purchasing an additional 139,096 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Cogent Biosciences during the third quarter valued at approximately $134,000. Finally, Bank of Montreal Can bought a new position in Cogent Biosciences in the third quarter worth approximately $3,135,000.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Robert W. Baird dropped their price objective on Cogent Biosciences from $10.00 to $8.00 and set a “neutral” rating on the stock in a research report on Thursday, February 27th. HC Wainwright lowered their price target on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Scotiabank began coverage on shares of Cogent Biosciences in a research note on Friday, March 7th. They set a “sector outperform” rating and a $17.00 price objective for the company. Piper Sandler raised Cogent Biosciences to a “strong-buy” rating in a research report on Friday, March 7th. Finally, Wedbush reissued a “neutral” rating and issued a $11.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, February 25th. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Cogent Biosciences has an average rating of “Moderate Buy” and an average target price of $14.43.

Cogent Biosciences Trading Down 2.0 %

Shares of COGT stock opened at $6.48 on Monday. The company has a market capitalization of $737.75 million, a P/E ratio of -2.61 and a beta of 1.80. The business’s 50 day moving average is $7.87 and its two-hundred day moving average is $9.09. Cogent Biosciences, Inc. has a 12-month low of $5.88 and a 12-month high of $12.61.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.